1. European Cardiovascular Disease Statistics 2012 edition.

2. Śliż D, Mamcarz A, Filipiak KJ i wsp. 3ST-POL trial: standards of statin use in Poland in the context of the European Society of Cardiology guidelines. Pol. Arch. Med. Wewn. 2010; 120(9): 328-333.

3. Śliż D, Filipiak KJ, Naruszewicz M i wsp. Standard of Statin usage in Poland in high risk patients: 3ST-POL study results. Kardiol. Pol. 2013; 73(3): 253-259.

4. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 1992; 33(11): 1569-1582.

5. Banach M, Filipiak KJ, Opolski G. Historia statyn. W: Banach M, Filipiak KJ, Opolski G (red.). Aktualny stan wiedzy na temat statyn. Termedia Wydawnictwa Medyczne, Poznań 2008.

6. Endo A. The origin of the statins. Atheroscler. Suppl. 2004; 5(3): 125-130.

7. Williams O, Jacks AM, Davis J i wsp. Case 10: Merck (A): Mevacor. W: Afuah A (red.). Innovation Management - Strategies, Implementation, and Profits. Oxford University Press, 1998.

8. Cunningham E. Is red yeast rice safe and effective for lowering serum cholesterol? J. Am. Diet. Assoc. 2011; 111(2): 324.

9. Gordon RY, Cooperman T, Obermeyer W i wsp. Marked variability of monacolin levels in commercial red yeast rice products: Buyer beware! Arch. Intern. Med. 2010; 170: 1722-1727.

10. Lin CC, Li TC, Lai MM. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 2005; 153(5): 679-686.

11. Wang J, Zongliang L, Chi J i wsp. Multicenter clinical trial of the serum lipid-lowering effects of a Monascus Purpureus (Red Yeast) rice preparation from traditional Chinese medicine. Current Therapeutic Research 1997; 58(12): 964-978.

12. Heber D, Yip I, Ashley J.M. i wsp. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am. J. Clin. Nutr. 1999; 69(2): 231-236.

13. Liu J, Zhang J, Shi Y i wsp. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin. Med. 2006; 1: 4.

14. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011; 32: 1769-1818.

15. Wożakowska-Kapłon B, Filipiak KJ, Mamcarz A i wsp. Aktualne problemy terapii dyslipidemii w Polsce - II Deklaracja Sopocka. Stanowisko grupy ekspertów wsparte przez Sekcję F farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiol. Pol. 2014; 72: 847-853.

16. Halbert SC, French B, Gordon RY i wsp. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am. J. Cardiol. 2010; 105(2): 198-204.